Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

分组1 - Theravance Biopharma reported a quarterly loss of $0.05 per share, consistent with the Zacks Consensus Estimate, compared to earnings of$0.03 per share a year ago [1] - The company posted revenues of $18.75 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 3.50$17.57 million year-over-year [2] - Over the last four quarters, Theravance Biopharma has surpassed consensus EPS estimates two times and revenue estimates two times [2][1] 分组2 - The stock has underperformed, losing about 4.7% since the beginning of the year, while the S&P 500 gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of$17.65 million, and for the current fiscal year, it is $0.84 on revenues of$111.23 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 50% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]